Literature DB >> 24659311

An assessment of iron overload in children treated for cancer and nonmalignant hematologic disorders.

Jelena Rascon, Lina Rageliene, Sigita Stankeviciene, Darius Palionis, Algirdas Edvardas Tamosiunas, Nomeda Valeviciene, Tadas Zvirblis.   

Abstract

UNLABELLED: Our goal was to assess the natural fate of iron overload (IO) following transfusions of packed red blood cells (PRBCs) in children treated for cancer and nonmalignant disorders according to the intensity level of their treatment. Sixty-six children were followed up from February 2010 to March 2013. The transfusion burden was compared between three treatment intensity groups assigned according to the Intensity of Treatment Rating Scale 3.0 (ITR-3). IO was assessed by serial measurements of serum ferritin (SF) (n= 66) and quantification of tissue iron by magnetic resonance imaging (MRI) (n=12). Of the children studied, 36 % (24/66) received moderately intensive treatment (level 2), 21 % (14/ 66) received very intensive treatment (level 3), and 42 % (28/ 66) received the most intensive treatment (level 4). The number of PRBC (p=0.016), the total transfused volume (p= 0.026), and transfused volume adjusted to body weight (p= 0.004) were significantly higher in the level 4 group. By the median follow-up time of 35.5 months (range 8–133), 21– 29 % of patients (including level 2 and level 3 children) had SF >1,000 μg/l 1 year after cessation of transfusions. The slowest decrease of SF was observed in the level 4 group. Initial MRI examination demonstrated either mild or moderate IO in the liver and spleen. Repetitive MRI showed significant improvement in relaxation time between the initial and follow-up MRI performances in the liver (5.9 vs. 8.6 ms, p= 0.03) and the spleen (4.3 vs. 8.8 ms, p=0.03).
CONCLUSION: IO diminished over time, but in the level 4 patients, it was detectable for years after cessation of transfusions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24659311     DOI: 10.1007/s00431-014-2295-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  28 in total

1.  Insidious iron burden in pediatric patients with acute lymphoblastic leukemia.

Authors:  Jennifer Eng; Jonathan D Fish
Journal:  Pediatr Blood Cancer       Date:  2011-03       Impact factor: 3.167

2.  Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major.

Authors:  Alan R Cohen; Ekkehard Glimm; John B Porter
Journal:  Blood       Date:  2007-10-19       Impact factor: 22.113

3.  Myocardial iron overload in transfusion-dependent pediatric patients with acute leukemia.

Authors:  K Lutz; G von Komorowski; M Dürken; R Engelhardt; D J Dinter
Journal:  Pediatr Blood Cancer       Date:  2008-11       Impact factor: 3.167

4.  On T2* magnetic resonance and cardiac iron.

Authors:  John-Paul Carpenter; Taigang He; Paul Kirk; Michael Roughton; Lisa J Anderson; Sofia V de Noronha; Mary N Sheppard; John B Porter; J Malcolm Walker; John C Wood; Renzo Galanello; Gianluca Forni; Gualtiero Catani; Gildo Matta; Suthat Fucharoen; Adam Fleming; Michael J House; Greg Black; David N Firmin; Timothy G St Pierre; Dudley J Pennell
Journal:  Circulation       Date:  2011-03-28       Impact factor: 29.690

5.  A revision of the intensity of treatment rating scale: classifying the intensity of pediatric cancer treatment.

Authors:  Anne E Kazak; Matthew C Hocking; Richard F Ittenbach; Anna T Meadows; Wendy Hobbie; Branlyn Werba DeRosa; Ann Leahey; Leslie Kersun; Anne Reilly
Journal:  Pediatr Blood Cancer       Date:  2011-08-19       Impact factor: 3.167

Review 6.  Contemporary approaches to treatment of beta-thalassemia intermedia.

Authors:  Ali T Taher; Khaled M Musallam; Mehran Karimi; Maria D Cappellini
Journal:  Blood Rev       Date:  2012-04       Impact factor: 8.250

7.  Survival of European children and young adults with cancer diagnosed 1995-2002.

Authors:  Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller
Journal:  Eur J Cancer       Date:  2009-02-21       Impact factor: 9.162

8.  Risk factors for hyperferritinemia secondary to red blood cell transfusions in pediatric cancer patients.

Authors:  Ali Amid; Nick Barrowman; Abi Vijenthira; Pat Lesser; Karen Mandel; Raveena Ramphal
Journal:  Pediatr Blood Cancer       Date:  2013-06-17       Impact factor: 3.167

9.  Iron overload in children undergoing cancer treatments.

Authors:  Maëlle de Ville de Goyet; Stéphane Moniotte; Annie Robert; Sophie Dupont; Christiane Vermylen; Francis Veyckemans; Bénédicte Brichard
Journal:  Pediatr Blood Cancer       Date:  2013-07-29       Impact factor: 3.167

10.  Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters.

Authors:  Päivi Halonen; Jorma Mattila; Pauli Suominen; Tarja Ruuska; Matti K Salo; Anne Mäkipernaa
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more
  3 in total

Review 1.  Secondary solid cancer screening following hematopoietic cell transplantation.

Authors:  Y Inamoto; N N Shah; B N Savani; B E Shaw; A A Abraham; I A Ahmed; G Akpek; Y Atsuta; K S Baker; G W Basak; M Bitan; Z DeFilipp; T K Gregory; H T Greinix; M Hamadani; B K Hamilton; R J Hayashi; D A Jacobsohn; R T Kamble; K A Kasow; N Khera; H M Lazarus; A K Malone; M T Lupo-Stanghellini; S P Margossian; L S Muffly; M Norkin; M Ramanathan; N Salooja; H Schoemans; J R Wingard; B Wirk; W A Wood; A Yong; C N Duncan; M E D Flowers; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-03-30       Impact factor: 5.483

2.  Change in liver, spleen and bone marrow magnetic resonance imaging signal intensity over time in children with solid abdominal tumors.

Authors:  Michael Sirignano; Jonathan R Dillman; Brian D Weiss; Charles T Quinn; Bin Zhang; Weizhe Su; Andrew T Trout
Journal:  Pediatr Radiol       Date:  2017-12-19

3.  Iron chelation effect of curcumin and baicalein on aplastic anemia mouse model with iron overload.

Authors:  Wu Dijiong; Wen Xiaowen; Xu Linlong; Liu Wenbin; Hu Huijin; Ye Baodong; Zhou Yuhong
Journal:  Iran J Basic Med Sci       Date:  2019-06       Impact factor: 2.699

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.